Cardiorenal Syndrome in Heart Failure

lt;p>W.H. Wilson Tang is research director and staff cardiologist in the Section of Heart Failure and Cardiac Transplantation Medicine at the Heart and Vascular Institute, Cleveland Clinic, U.S.A. As a clinician-scientist and practicing heart failure/transplant cardiologist specialized in cardiomyopathies and kidney-/cancer-related heart diseases, Dr. Tang's translational research focuses on understanding the cellular and molecular mechanisms that contribute to disease progression in heart failure and cardio-renal diseases.  He has been elected as member of the American Society of Clinical Investigation in 2013 for his contributions to mechanistic understanding of cardio-renal syndromes, and the Association of American Physicians in 2018 for studying the contributing role of diet and microbiome in cardiovascular diseases.  Dr. Tang has authored over 600 peer-reviewed scientific publications, editorials, and book chapters, and has served as Board of Directors in the Heart Failure Society of America (HFSA), as well as member of the writing committee for American College of Cardiology (ACC)/American Heart Association (AHA) clinical guidelines in the management of heart failure. 

Frederik H. Verbrugge is a cardiologist with a dedicated interest in heart failure, hemodynamics and renal physiology. Dr. Verbrugge graduated as an M.D. in 2010 and obtained his Ph.D. degree in 2015 with his doctoral thesis entitled "Phenotyping the heart failure syndrome: towards individualized patient care". He is currently a research fellow at Mayo Clinic (Rochester, MN, USA) and has published over 70 peer-reviewed articles in the field of cardiology and heart failure.

Wilfried Mullens is cardiologist and professor of physiology at Ziekenhuis Oost-Limburg (Genk, Belgium) and Hasselt University (Diepenbeek, Belgium), respectively. Prof. Mullens has published over 150 peer-reviewed articles, has been president of the Belgian Working Group on Heart Failure (BWGHF), Coordinator of the CardioRenal Study group of the European Heart Failure Association (HFA), and board member of the HFA.

Introduction: Refining Physiologic-Based Individualized Management of Cardio-Renal Syndrome.- 1. A Historical Perspective on Evolving Concepts of Cardio-Renal Syndrome in Heart Failure.- 2. Hemodynamic Insights to Cardio-Renal Syndrome: A View Looking Back to See Forward.- Part 1. Insights from Pathophysiologic Mechanisms.- 3. Mechanisms of Cardio-Renal Syndrome: From Molecular Pathways to Novel Therapeutics.- 4. Pathophysiology of Cardio-Renal Syndrome: Autonomic Mechanisms.- 5. Insights on Diuretic Therapy from Clinical and Pharmacologic Perspectives.- Part 2: Case-Based Discussions.- 6. A patient with chronic kidney disease and heart failure with reduced ejection fraction.- 7. A patient with chronic kidney disease and heart failure with preserved ejection fraction.- 8. Heart Failure in a Patient with End-Stage Kidney Disease and Renal Replacement Therapy.- 9. Loop diuretic resistance in a patient with chronic heart failure.- 10. Worsening renal function in a patient with acute heartfailure and volume overload.- 11. Loop diuretic resistance in a patient with acute heart failure.- 12: Diuretic therapy complicated by hyponatremia.- 13. A patient with abdominal congestion.- 14. Hepatorenal Dysfunction in a Patient with Advanced Heart Failure.- 15. Low output heart failure: the cold and wet patient.- 16. Cardio-Renal Syndrome in a Patient with Mechanical Circulatory Support.- 17. Patient with Severe Right Heart Failure.- 18. Refractory congestion - when to use ultrafiltration?